Clinical Trials Logo

Clinical Trial Summary

The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effective rate of systemic treatment is low. SBRT has the characteristics of high dose in tumor target area and low dose in surrounding normal tissues. In theory, SBRT is more conducive to the protection of normal tissues and can potentially be used in the salvage treatment of recurrent lesions after radiotherapy. Even so, SBRT is still controversial in the rescue treatment of recurrent lung cancer after radiotherapy, especially for "ultral-central" lesions close to mediastinal structures (such as bronchus, esophagus and large blood vessels), which have a high probability of fatal side effects. However, a few studies on the application of SBRT in the reirradiation for ultral-central lung cancer have shown acceptable safety and efficacy. Generally speaking, there are few studies on SBRT in the treatment of recurrent ultral-central tumor with limited data. The purpose of this study is to further evaluate the efficacy and toxicities of SBRT in the treatment of recurrent ultral-central tumors after radiotherapy.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05189054
Study type Observational
Source Peking University Third Hospital
Contact Zhe Ji, M.D.
Phone 008618710002823
Email [email protected]
Status Not yet recruiting
Start date January 1, 2022
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05043922 - A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma Phase 2
Recruiting NCT05045040 - Mobile-based Empathic Communication Support Program to Promote Advance Care Planning Discussion in Advanced Cancer Patients N/A
Not yet recruiting NCT04784221 - Reirradiation by Nanoparticles and Hypofractionated Protontherapy of Relapsed Tumors: Non-randomized Phase II Study. Phase 2
Recruiting NCT04596865 - Recurrence After Whipple's (RAW) Study
Recruiting NCT03441100 - TCR-engineered T Cells in Solid Tumors: IMA202-101 Phase 1
Recruiting NCT03686124 - TCR-engineered T Cells in Solid Tumors Phase 1
Recruiting NCT04889742 - Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors Phase 2
Completed NCT03132038 - Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT02410187 - SBRT for Extra-cranial Oligorecurrent Tumor Phase 2
Recruiting NCT03941262 - Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Phase 1
Recruiting NCT03760952 - Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Active, not recruiting NCT03758781 - IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Phase 1
Recruiting NCT04204850 - Cabozantinib to Treat Recurrent Liver Cancer Post Transplant Phase 2
Recruiting NCT05002140 - Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients Phase 1
Recruiting NCT04421560 - Pembrolizumab, Ibrutinib and Rituximab in PCNSL Phase 1/Phase 2
Completed NCT04326088 - Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer